Our website does not fully support your browser.

We've detected that you are using an older version of Internet Explorer. Your commerce experience may be limited. Please update your browser to Internet Explorer 11 or above.

Limited Functionality Warning

We are currently updating our network. During this time, certain functionality may be unavailable, including online orders. We apologize for any inconvenience this may cause you.

Please contact Customer Service with any questions or comments.
Phone: (608) 274-4330
Toll-Free Phone: (800) 356-9526
Email: custserv@promega.com
Hours: 7am – 6pm, CST, Monday-Friday

We believe this site might serve you best:

United States

United States

Language: English

Promega's Cookie Policy

Our website uses functional cookies that do not collect any personal information or track your browsing activity. When you select your country, you agree that we can place these functional cookies on your device.

A Novel MOA-Based Bioluminescent Bioassay for Quantitative Measurement of anti-VEGF Antibody Potency and Stability

Part # PS319

Abstract

Jennifer Wilkinson, Matt Robers, Frank Fan and Mei Cong
Promega Corporation, 2800 Woods Hollow Rd, Madison, WI 53711


We have developed a bioluminescent reporter-based bioassay that measures VEGF stimulation/inhibition of KDR (VEGFR2). This assay overcomes many of the limitations of the current endothelial cell proliferation assays, and can be used for the discovery and development of novel biologic therapies aimed at either inducing or inhibiting the VEGF response.

Printed in USA.